448 related articles for article (PubMed ID: 34418266)
41. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
42. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
43. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles.
Huang X; Li A; Xu P; Yu Y; Li S; Hu L; Feng S
J Nanobiotechnology; 2023 Jun; 21(1):184. PubMed ID: 37291577
[TBL] [Abstract][Full Text] [Related]
44. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
Jacinto FV; Link W; Ferreira BI
J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
[TBL] [Abstract][Full Text] [Related]
45. Stimulus-Responsive Smart Nanoparticles-Based CRISPR-Cas Delivery for Therapeutic Genome Editing.
Naeem M; Hoque MZ; Ovais M; Basheer C; Ahmad I
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681959
[TBL] [Abstract][Full Text] [Related]
46. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
47. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
Ma T; Chen X; Wang M
Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
[TBL] [Abstract][Full Text] [Related]
48. Exosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants.
Alghuthaymi MA; Ahmad A; Khan Z; Khan SH; Ahmed FK; Faiz S; Nepovimova E; Kuča K; Abd-Elsalam KA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299081
[TBL] [Abstract][Full Text] [Related]
49. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells.
Hindriksen S; Bramer AJ; Truong MA; Vromans MJM; Post JB; Verlaan-Klink I; Snippert HJ; Lens SMA; Hadders MA
PLoS One; 2017; 12(6):e0179514. PubMed ID: 28640891
[TBL] [Abstract][Full Text] [Related]
50. CRISPR/Cas9 Genome Editing vs. Over-Expression for Fluorescent Extracellular Vesicle-Labeling: A Quantitative Analysis.
Strohmeier K; Hofmann M; Hauser F; Sivun D; Puthukodan S; Karner A; Sandner G; Le Renard PE; Jacak J; Mairhofer M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008709
[TBL] [Abstract][Full Text] [Related]
51. In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.
Huang K; Zapata D; Tang Y; Teng Y; Li Y
Biomaterials; 2022 Dec; 291():121876. PubMed ID: 36334354
[TBL] [Abstract][Full Text] [Related]
52. Preparation of NanoMEDIC Extracellular Vesicles to Deliver CRISPR-Cas9 Ribonucleoproteins for Genomic Exon Skipping.
Watanabe K; Gee P; Hotta A
Methods Mol Biol; 2023; 2587():427-453. PubMed ID: 36401042
[TBL] [Abstract][Full Text] [Related]
53. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
[TBL] [Abstract][Full Text] [Related]
54. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Chen F; Alphonse M; Liu Q
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
[TBL] [Abstract][Full Text] [Related]
55. Encapsulating Cas9 into extracellular vesicles by protein myristoylation.
Whitley JA; Kim S; Lou L; Ye C; Alsaidan OA; Sulejmani E; Cai J; Desrochers EG; Beharry Z; Rickman CB; Klingeborn M; Liu Y; Xie ZR; Cai H
J Extracell Vesicles; 2022 Apr; 11(4):e12196. PubMed ID: 35384352
[TBL] [Abstract][Full Text] [Related]
56. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
57. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina.
Yang TC; Chang CY; Yarmishyn AA; Mao YS; Yang YP; Wang ML; Hsu CC; Yang HY; Hwang DK; Chen SJ; Tsai ML; Lai YH; Tzeng Y; Chang CC; Chiou SH
Acta Biomater; 2020 Jan; 101():484-494. PubMed ID: 31672582
[TBL] [Abstract][Full Text] [Related]
58. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.
Dong W; Kantor B
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372494
[TBL] [Abstract][Full Text] [Related]
59. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy.
Wang L; Zheng W; Liu S; Li B; Jiang X
Chembiochem; 2019 Mar; 20(5):634-643. PubMed ID: 30393919
[TBL] [Abstract][Full Text] [Related]
60. Advances in therapeutic application of CRISPR-Cas9.
Sun J; Wang J; Zheng D; Hu X
Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
